Brief: Karolinska Development's Portfolio Co Reports Positive Results From Clinical Study Of Drug Candidate

Kdventures AB

02/10/2023 09:55

Oct 2 (Reuters) - Karolinska Development AB  KDEV.ST :
    * REG-KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY PHARMNOVO
REPORTS
POSITIVE RESULTS FROM A CLINICAL PHASE 1 STUDY OF DRUG CANDIDATE
PN6047
    * RESULTS FROM STUDY SHOW THAT PN6047 IS SAFE AND
WELL-TOLERATED
AT DOSES PREDICTED TO HAVE CLINICALLY RELEVANT EFFECTS
    * PN6047 SEEMS TO OFFER A DIFFERENT SAFETY PROFILE COMPARED
TO
CONVENTIONAL OPIOIDS

Source text for Eikon:  ID:nGNE5FfVZl 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))